Illumina said revenue for 2025 was $3,184 million, down 3% from $3,268 million in 2024. The company said service and other revenue and instruments revenue decreased, while consumables revenue increased.

1. 01

   Illumina said revenue for 2025 was $3,184 million, down 3% from $3,268 million in 2024. The company said service and other revenue and instruments revenue decreased, while consumables revenue increased.

2. 02

   Illumina said income from operations for 2025 was $606 million, compared with a loss from operations of $1,008 million in 2024. The company said GRAIL recognized goodwill and intangible asset impairment of $1,886 million in 2024.

3. 03

   On June 22, 2025, Illumina entered into a Stock Purchase Agreement with Standard BioTools to acquire SomaLogic and other specified assets for $350 million in cash, with up to $75 million in potential milestone payments, and the company expects the transaction to close in the first half of 2026.

4. 04

   Illumina said net cash provided by operating activities for 2025 was $758 million, and net cash used in financing activities was $681 million, of which $700 million was used for share repurchases. As of September 28, 2025, cash and cash equivalents totaled $1,050 million.

Key figures

Quarter ended September 28, 2025

Revenue

$1.1B

Operating income

$227M

Net income

$150M

EPS

$0.98

Gross profit

$733M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.